At the conclusion of the 42-day postsurgery study period, the incidences of acute rejection
and of toxicity requiring tacrolimus dosage adjustment were the outcomes measured.
28,33,42) Cytomegalovirus enteritis may clinically mimic acute rejection
with symptoms of diarrhea and epigastric pain.
20) pointed out higher acute rejection
incidence in female recipients in the first 6 months and declared early mortality (< 6 months) caused by infection.
following lung transplantation: Limitations in accuracy of thin-section CT for diagnosis.
In pediatric patients, the safety and efficacy of Rapamune have not been established in kidney transplant patients less than 13 years old, or in patients less than 18 years old who are considered at high risk of acute rejection
in renal transplantation recipients treated with tacrolimus prolonged release- and immediate release-based therapy - the OSAKA study (oral presentation by Professor Dr Bernhard Banas, University Medical Center Regensburg, Germany)
2]-monitored patients, with no significant effect on the rate of acute rejection
for a majority of these studies.
African -American recipients also are more likely than Caucasians to experience acute rejection
ATG-Fresenius S is an immunosuppressive polyclonal antibody product for the prevention and treatment of acute rejection
following organ transplantation.
Despite recent advances in immunosuppressive agents, from 20% to 60% of the 12,000 US patients who receive kidney transplants each year experience acute rejection
during the first year following transplantation.
CTI says the primary endpoint of the trial is defined as non-inferiority in biopsy proven acute rejection
(BPAR) episodes in patients receiving ISA247 for six months compared to the tacrolimus control.
Thymoglobulin(R) (Anti-thymocyte globulin (Rabbit)) was introduced to the US market in 1999 for the treatment of renal transplant acute rejection
, and according to IMS data has since captured the top spot in US immunosuppressive antibody therapies.
The 6-month results revealed that Prograf(R) in combination with the higher dose of sirolimus (2mg) was associated with a significantly lower incidence of biopsy-proven acute rejection
The company says myfortic successfully completed the European Mutual Recognition Procedure (MRP) and was approved for the prevention of acute rejection
of kidney allografts in adult patients on February 7, 2004.
Thymoglobulin, a drug that could prevent organ loss for kidney transplant recipients experiencing acute rejection
, was already the market leader in Europe and is now the worldwide leader in immunosuppressive antibodies.